# A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis

> **NCT07270003** · NA · RECRUITING · sponsor: **Xijing Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Palmoplantar Pustulosis (PPP)

## Interventions

- **DRUG:** Ivarmacitinib

## Key facts

- **NCT ID:** NCT07270003
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07270003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07270003, "A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07270003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*